

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**Form 10-Q**

---

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2012**

or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_**

**Commission file number: 1-10864**

---

**UNITEDHEALTH GROUP®**

**UnitedHealth Group Incorporated**  
(Exact name of registrant as specified in its charter)

---

**Minnesota**  
(State or other jurisdiction of  
incorporation or organization)

**41-1321939**  
(I.R.S. Employer  
Identification No.)

**UnitedHealth Group Center**  
**9900 Bren Road East**  
**Minnetonka, Minnesota**  
(Address of principal executive offices)

**55343**  
(Zip Code)

**(952) 936-1300**  
(Registrant's telephone number, including area code)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated  Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of April 30, 2012, there were 1,037,448,473 shares of the registrant's Common Stock, \$.01 par value per share, issued and outstanding.

---

---

# UNITEDHEALTH GROUP

## Table of Contents

	<u>Page</u>
Part I. Financial Information	
Item 1. Financial Statements .....	1
Condensed Consolidated Balance Sheets as of March 31, 2012 and December 31, 2011 .....	1
Condensed Consolidated Statements of Operations for the three months ended March 31, 2012 and 2011 .....	2
Condensed Consolidated Statements of Comprehensive Income for the three months ended March 31, 2012 and 2011 .....	3
Condensed Consolidated Statements of Changes in Shareholders' Equity for the three months ended March 31, 2012 and 2011 .....	4
Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2012 and 2011 .....	5
Notes to the Condensed Consolidated Financial Statements .....	6
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations ...	23
Item 3. Quantitative and Qualitative Disclosures about Market Risk .....	34
Item 4. Controls and Procedures .....	35
Part II. Other Information	
Item 1. Legal Proceedings .....	35
Item 1A. Risk Factors .....	35
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds .....	35
Item 5. Other Information .....	36
Item 6. Exhibits .....	37
Signatures .....	38

**PART I. FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**UnitedHealth Group  
Condensed Consolidated Balance Sheets  
(Unaudited)**

<b>(in millions, except per share data)</b>	<b>March 31, 2012</b>	<b>December 31, 2011</b>
<b>Assets</b>		
Current assets:		
Cash and cash equivalents .....	\$ 11,661	\$ 9,429
Short-term investments .....	2,665	2,577
Accounts receivable, net .....	2,688	2,294
Other current receivables, net .....	1,978	2,255
Assets under management.....	2,568	2,708
Deferred income taxes .....	432	472
Prepaid expenses and other current assets .....	698	615
Total current assets.....	<u>22,690</u>	<u>20,350</u>
Long-term investments .....	16,492	16,166
Property, equipment and capitalized software, net.....	2,560	2,515
Goodwill.....	25,754	23,975
Other intangible assets, net .....	3,103	2,795
Other assets .....	2,091	2,088
Total assets.....	<u>\$ 72,690</u>	<u>\$ 67,889</u>
<b>Liabilities and shareholders' equity</b>		
Current liabilities:		
Medical costs payable .....	\$ 10,221	\$ 9,799
Accounts payable and accrued liabilities .....	6,197	6,853
Other policy liabilities.....	5,457	5,063
Commercial paper and current maturities of long-term debt.....	1,771	982
Unearned revenues.....	3,816	1,225
Total current liabilities .....	<u>27,462</u>	<u>23,922</u>
Long-term debt, less current maturities .....	11,083	10,656
Future policy benefits.....	2,444	2,445
Deferred income taxes and other liabilities.....	2,845	2,574
Total liabilities.....	<u>43,834</u>	<u>39,597</u>
Commitments and contingencies (Note 8)		
Shareholders' equity:		
Preferred stock, \$0.001 par value - 10 shares authorized; no shares issued or outstanding ..	—	—
Common stock, \$0.01 par value - 3,000 shares authorized; 1,033 and 1,039 issued and outstanding.....	10	10
Retained earnings.....	28,388	27,821
Accumulated other comprehensive income .....	458	461
Total shareholders' equity.....	<u>28,856</u>	<u>28,292</u>
Total liabilities and shareholders' equity.....	<u>\$ 72,690</u>	<u>\$ 67,889</u>

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Operations**  
**(Unaudited)**

(in millions, except per share data)	Three Months Ended March 31,	
	2012	2011
Revenues:		
Premiums .....	\$ 24,631	\$ 23,003
Services .....	1,791	1,598
Products.....	688	649
Investment and other income .....	172	182
Total revenues.....	27,282	25,432
Operating costs:		
Medical costs.....	19,939	18,725
Operating costs.....	4,096	3,617
Cost of products sold.....	634	599
Depreciation and amortization .....	296	270
Total operating costs.....	24,965	23,211
Earnings from operations .....	2,317	2,221
Interest expense .....	(148)	(118)
Earnings before income taxes .....	2,169	2,103
Provision for income taxes .....	(781)	(757)
Net earnings.....	\$ 1,388	\$ 1,346
Basic net earnings per common share .....	\$ 1.34	\$ 1.24
Diluted net earnings per common share .....	\$ 1.31	\$ 1.22
Basic weighted-average number of common shares outstanding .....	1,039	1,086
Dilutive effect of common stock equivalents.....	21	13
Diluted weighted-average number of common shares outstanding .....	1,060	1,099
Anti-dilutive shares excluded from the calculation of dilutive effect of common stock equivalents.....	24	60
Cash dividends declared per common share .....	\$ 0.1625	\$ 0.1250

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Comprehensive Income**  
**(Unaudited)**

(in millions)	Three Months Ended March 31,	
	2012	2011
Net earnings.....	\$ 1,388	\$ 1,346
Other comprehensive loss:		
Gross unrealized holding gains (losses) on investment securities during the period.....	30	(37)
Income tax (expense) benefit.....	(11)	14
Total unrealized gains (losses), net of tax.....	19	(23)
Gross reclassification adjustment for net realized gains included in net earnings.....	(39)	(48)
Income tax benefit.....	14	17
Total reclassification adjustment, net of tax.....	(25)	(31)
Foreign currency translation adjustments.....	3	9
Other comprehensive loss.....	(3)	(45)
Comprehensive income.....	\$ 1,385	\$ 1,301

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Changes in Shareholders' Equity**  
**(Unaudited)**

(in millions)	Common Stock		Additional Paid-In Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)		Total Shareholders' Equity
	Shares	Amount			Net Unrealized Gains (Losses) on Investments	Foreign Currency Translation (Losses) Gains	
Balance at January 1, 2012 .....	1,039	\$ 10	\$ —	\$27,821	\$ 476	\$ (15)	\$ 28,292
Net earnings .....				1,388			1,388
Other comprehensive (loss) income...					(6)	3	(3)
Issuances of common stock, and related tax effects .....	13	—	129				129
Share-based compensation, and related tax benefits .....			209				209
Common stock repurchases .....	(19)	—	(338)	(653)			(991)
Common stock dividends.....				(168)			(168)
Balance at March 31, 2012 .....	1,033	\$ 10	\$ —	\$28,388	\$ 470	\$ (12)	\$ 28,856
Balance at January 1, 2011 .....	1,086	\$ 11	\$ —	\$25,562	\$ 280	\$ (28)	\$ 25,825
Net earnings .....				1,346			1,346
Other comprehensive (loss) income...					(54)	9	(45)
Issuances of common stock, and related tax effects .....	6	—	61				61
Share-based compensation, and related tax benefits .....			139				139
Common stock repurchases .....	(15)	—	(200)	(420)			(620)
Common stock dividends.....				(135)			(135)
Balance at March 31, 2011 .....	1,077	\$ 11	\$ —	\$26,353	\$ 226	\$ (19)	\$ 26,571

See Notes to the Condensed Consolidated Financial Statements

**UnitedHealth Group**  
**Condensed Consolidated Statements of Cash Flows**  
**(Unaudited)**

(in millions)	Three Months Ended March 31,	
	2012	2011
<b>Operating activities</b>		
Net earnings.....	\$ 1,388	\$ 1,346
Noncash items:		
Depreciation and amortization .....	296	270
Deferred income taxes.....	126	165
Share-based compensation .....	140	123
Other, net.....	(88)	(23)
Net change in other operating items, net of effects from acquisitions and changes in AARP balances:		
Accounts receivable .....	(316)	(385)
Other assets .....	(221)	(304)
Medical costs payable .....	246	143
Accounts payable and other liabilities .....	(202)	48
Other policy liabilities.....	(248)	(8)
Unearned revenues .....	2,465	(151)
Cash flows from operating activities .....	<u>3,586</u>	<u>1,224</u>
<b>Investing activities</b>		
Purchases of investments.....	(2,326)	(2,716)
Sales of investments .....	1,034	1,085
Maturities of investments .....	1,098	1,048
Cash paid for acquisitions, net of cash assumed .....	(1,935)	(541)
Purchases of property, equipment and capitalized software.....	(269)	(213)
Cash flows used for investing activities .....	<u>(2,398)</u>	<u>(1,337)</u>
<b>Financing activities</b>		
Common stock repurchases .....	(991)	(620)
Proceeds from common stock issuances .....	257	96
Dividends paid.....	(168)	(135)
Proceeds from commercial paper, net .....	244	759
Proceeds from issuance of long-term debt .....	995	747
Repayments of long-term debt .....	—	(955)
Customer funds administered.....	1,137	1,050
Checks outstanding in excess of bank deposits .....	(247)	(183)
Other, net.....	(183)	21
Cash flows from financing activities .....	<u>1,044</u>	<u>780</u>
Increase in cash and cash equivalents .....	2,232	667
Cash and cash equivalents, beginning of period .....	9,429	9,123
Cash and cash equivalents, end of period.....	<u>\$ 11,661</u>	<u>\$ 9,790</u>

See Notes to the Condensed Consolidated Financial Statements

**UNITEDHEALTH GROUP**  
**NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**1. Basis of Presentation**

UnitedHealth Group Incorporated (also referred to as “UnitedHealth Group” and the “Company”) is a diversified health and well-being company dedicated to helping people live healthier lives and making health care work better. We offer a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.

The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The Company has eliminated intercompany balances and transactions. The year-end condensed consolidated balance sheet data was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2011 as filed with the SEC (2011 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.

***Use of Estimates***

These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to medical costs payable and medical costs, premium rebates and risk-sharing provisions related to revenues, valuation and impairment analysis of goodwill and other intangible assets, other policy liabilities, other current receivables, valuation of investments, income taxes and contingent liabilities. These estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any changes in estimates is included in earnings in the period in which the estimate is adjusted.

***Accounting Policies***

Following is an expanded portion of the Company's revenue policy related to premium rebates. All other accounting policies disclosed in Note 2 of Notes to the Consolidated Financial Statements in the 2011 10-K remain unchanged.

Effective in 2011, premium revenues subject to premium rebates of the Patient Protection and Affordable Care Act and a reconciliation measure, the Health Care and Education Reconciliation Act of 2010 (Health Reform Legislation) are recognized based on the estimated premium earned net of the projected rebates over the period of the contract because the Company is able to reasonably estimate ultimate premium. Each period the Company estimates premium rebates based on expected refunds required. The most significant factors in estimating these rebates are financial performance within each aggregation set (e.g. by state, group size and licensed subsidiary), including medical claim experience and effective tax rates, as well as changes in business mix and regulatory requirements. The estimated ultimate premium is revised each period to reflect current experience.

***Recently Adopted Accounting Standards***

In May 2011, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs” (ASU 2011-04). This update provides guidance on how fair value measurement should be applied where existing GAAP already requires or permits fair value measurements. In addition, ASU 2011-04 requires expanded disclosures regarding fair value measurements. ASU 2011-04 became effective for the Company's fiscal year 2012. The adoption of the measurement guidance of ASU 2011-04 did not have a material impact on the Condensed Consolidated Financial Statements. The new disclosures have been included with the Company's fair value disclosures in Note 3 of Notes to the Condensed Consolidated Financial Statements.

In June 2011, the FASB issued ASU No. 2011-05, “Comprehensive Income (Topic 220) - Presentation of Comprehensive Income” (ASU 2011-05). ASU 2011-05 requires entities to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements and eliminates the option to present the components of other comprehensive income as a part of the statement of equity. In December 2011, the FASB issued ASU No. 2011-12, “Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05” (ASU 2011-12). ASU 2011-12 defers the requirement to present reclassification



adjustments for each component of other comprehensive income on the face of the financial statements. ASU 2011-05 and ASU 2011-12 became effective for the Company's fiscal year 2012. The Company presented the components of other comprehensive income in separate Condensed Consolidated Statements of Comprehensive Income, which appear consecutive to the Condensed Consolidated Statements of Operations.

The Company has determined that there have been no other recently adopted or issued accounting standards that had or will have a material impact on its Condensed Consolidated Financial Statements.

## 2. Investments

A summary of short-term and long-term investments is as follows:

(in millions)	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
<b>March 31, 2012</b>				
Debt securities - available-for-sale:				
U.S. government and agency obligations .....	\$ 2,535	\$ 40	\$ (5)	\$ 2,570
State and municipal obligations.....	6,135	363	(2)	6,496
Corporate obligations.....	5,970	224	(6)	6,188
U.S. agency mortgage-backed securities.....	2,310	78	(1)	2,387
Non-U.S. agency mortgage-backed securities.....	459	34	—	493
Total debt securities - available-for-sale.....	<u>17,409</u>	<u>739</u>	<u>(14)</u>	<u>18,134</u>
Equity securities - available-for-sale .....	556	23	(2)	577
Debt securities - held-to-maturity:				
U.S. government and agency obligations .....	171	6	—	177
State and municipal obligations.....	33	—	—	33
Corporate obligations.....	242	—	(3)	239
Total debt securities - held-to-maturity.....	<u>446</u>	<u>6</u>	<u>(3)</u>	<u>449</u>
Total investments .....	<u>\$ 18,411</u>	<u>\$ 768</u>	<u>\$ (19)</u>	<u>\$ 19,160</u>
<b>December 31, 2011</b>				
Debt securities - available-for-sale:				
U.S. government and agency obligations .....	\$ 2,319	\$ 54	\$ —	\$ 2,373
State and municipal obligations.....	6,363	403	(1)	6,765
Corporate obligations.....	5,825	205	(23)	6,007
U.S. agency mortgage-backed securities.....	2,279	74	—	2,353
Non-U.S. agency mortgage-backed securities.....	476	28	—	504
Total debt securities - available-for-sale.....	<u>17,262</u>	<u>764</u>	<u>(24)</u>	<u>18,002</u>
Equity securities - available-for-sale .....	529	23	(8)	544
Debt securities - held-to-maturity:				
U.S. government and agency obligations .....	166	7	—	173
State and municipal obligations.....	13	—	—	13
Corporate obligations.....	18	—	—	18
Total debt securities - held-to-maturity.....	<u>197</u>	<u>7</u>	<u>—</u>	<u>204</u>
Total investments .....	<u>\$ 17,988</u>	<u>\$ 794</u>	<u>\$ (32)</u>	<u>\$ 18,750</u>

Included in the Company's investment portfolio were securities collateralized by sub-prime home equity lines of credit with fair values of \$2 million at both March 31, 2012 and December 31, 2011. Also included were Alt-A securities with fair values of \$9 million at both March 31, 2012 and December 31, 2011.

The fair values of the Company's mortgage-backed securities by credit rating (when multiple credit ratings are available for an individual security, the average of the available ratings is used) and origination as of March 31, 2012 were as follows:

(in millions)	AAA	AA	A	Non-Investment Grade	Total Fair Value
2012.....	\$ 6	\$ —	\$ —	\$ —	\$ 6
2011.....	26	—	—	—	26
2010.....	—	3	—	—	3
2007.....	86	—	—	3	89
2006.....	166	—	—	10	176
Pre - 2006.....	187	—	3	3	193
U.S. agency mortgage-backed securities....	2,387	—	—	—	2,387
Total.....	<u>\$ 2,858</u>	<u>\$ 3</u>	<u>\$ 3</u>	<u>\$ 16</u>	<u>\$ 2,880</u>

The amortized cost and fair value of available-for-sale debt securities as of March 31, 2012, by contractual maturity, were as follows:

(in millions)	Amortized Cost	Fair Value
Due in one year or less.....	\$ 2,730	\$ 2,742
Due after one year through five years.....	5,945	6,155
Due after five years through ten years.....	4,281	4,563
Due after ten years.....	1,684	1,794
U.S. agency mortgage-backed securities.....	2,310	2,387
Non-U.S. agency mortgage-backed securities.....	459	493
Total debt securities - available-for-sale.....	<u>\$ 17,409</u>	<u>\$ 18,134</u>

The amortized cost and fair value of held-to-maturity debt securities as of March 31, 2012, by contractual maturity, were as follows:

(in millions)	Amortized Cost	Fair Value
Due in one year or less.....	\$ 70	\$ 70
Due after one year through five years.....	135	138
Due after five years through ten years.....	198	195
Due after ten years.....	43	46
Total debt securities - held-to-maturity.....	<u>\$ 446</u>	<u>\$ 449</u>

The fair value of available-for-sale investments with gross unrealized losses by investment type and length of time that individual securities have been in a continuous unrealized loss position were as follows:

(in millions)	Less Than 12 Months		12 Months or Greater		Total	
	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses	Fair Value	Gross Unrealized Losses
<b>March 31, 2012</b>						
Debt securities - available-for-sale:						
U.S. government and agency obligations.....	\$ 845	\$ (5)	\$ —	\$ —	\$ 845	\$ (5)
State and municipal obligations.....	246	(2)	—	—	246	(2)
Corporate obligations .....	764	(5)	25	(1)	789	(6)
U.S. agency mortgage-back securities .....	176	(1)	—	—	176	(1)
Total debt securities - available-for-sale...	<u>\$ 2,031</u>	<u>\$ (13)</u>	<u>\$ 25</u>	<u>\$ (1)</u>	<u>\$ 2,056</u>	<u>\$ (14)</u>
Equity securities - available-for-sale .....	<u>\$ 2</u>	<u>\$ (1)</u>	<u>\$ 5</u>	<u>\$ (1)</u>	<u>\$ 7</u>	<u>\$ (2)</u>
<b>December 31, 2011</b>						
Debt securities - available-for-sale:						
State and municipal obligations.....	\$ 85	\$ (1)	\$ 21	\$ —	\$ 106	\$ (1)
Corporate obligations .....	1,496	(22)	28	(1)	1,524	(23)
Total debt securities - available-for-sale...	<u>\$ 1,581</u>	<u>\$ (23)</u>	<u>\$ 49</u>	<u>\$ (1)</u>	<u>\$ 1,630</u>	<u>\$ (24)</u>
Equity securities - available-for-sale .....	<u>\$ 24</u>	<u>\$ (7)</u>	<u>\$ 3</u>	<u>\$ (1)</u>	<u>\$ 27</u>	<u>\$ (8)</u>

The unrealized losses from all securities as of March 31, 2012 were generated from 1,600 positions out of a total of 16,100 positions. The Company believes that it will collect the principal and interest due on its investments that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit ratings associated with these securities. At each reporting period, the Company evaluates securities for impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the underlying credit quality and credit ratings of the issuers, noting neither a significant deterioration since purchase nor other factors leading to an other-than-temporary impairment (OTTI). As of March 31, 2012, the Company did not have the intent to sell any of the securities in an unrealized loss position.

As of March 31, 2012, the Company's holdings of non-U.S. agency mortgage-backed securities included \$7 million of commercial mortgage loans in default. These loans represented less than 1% of the Company's total mortgage-backed security holdings as of March 31, 2012.

A portion of the Company's investments in equity securities and venture capital funds consists of investments held in various public and nonpublic companies concentrated in the areas of health care services and related information technologies. Market conditions that affect the value of health care and related technology stocks will likewise impact the value of the Company's equity portfolio. The equity securities and venture capital funds were evaluated for severity and duration of unrealized loss, overall market volatility and other market factors.

Net realized gains included in Investment and Other Income on the Condensed Consolidated Statements of Operations were from the following sources:

(in millions)	Three Months Ended March 31,	
	2012	2011
Total OTTI.....	\$ (3)	\$ (4)
Portion of loss recognized in other comprehensive income .....	—	—
Net OTTI recognized in earnings .....	(3)	(4)
Gross realized losses from sales .....	(1)	(1)
Gross realized gains from sales.....	43	53
Net realized gains.....	<u>\$ 39</u>	<u>\$ 48</u>

### 3. Fair Value

Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP. In instances in which the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement is categorized in its entirety based on the lowest level input that is significant to the fair value measurement in its entirety. The Company's assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability.

The fair value hierarchy is summarized as follows:

*Level 1* — Quoted prices (unadjusted) for identical assets/liabilities in active markets.

*Level 2* — Other observable inputs, either directly or indirectly, including:

- Quoted prices for similar assets/liabilities in active markets;
- Quoted prices for identical or similar assets/liabilities in non-active markets (e.g., few transactions, limited information, non-current prices, high variability over time);
- Inputs other than quoted prices that are observable for the asset/liability (e.g., interest rates, yield curves, implied volatilities, credit spreads); and
- Inputs that are corroborated by other observable market data.

*Level 3* — Unobservable inputs that cannot be corroborated by observable market data.

Transfers between levels, if any, are recorded as of the beginning of the reporting period in which the transfer occurs; there were no transfers between Levels 1, 2 or 3 of any financial assets or liabilities during 2012 or 2011.

The following methods and assumptions were used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument included in the tables below:

**Cash and Cash Equivalents.** The carrying value of cash and cash equivalents approximates fair value as maturities are less than three months. Fair values of cash equivalent instruments that do not trade on a regular basis in active markets are classified as Level 2.

**Debt and Equity Securities.** Fair values of debt and equity securities are based on quoted market prices, where available. The Company obtains one price for each security primarily from a third-party pricing service (pricing service), which generally uses quoted or other observable inputs for the determination of fair value. The pricing service normally derives the security prices through recently reported trades for identical or similar securities, making adjustments through the reporting date based upon available observable market information. For securities not actively traded, the pricing service may use quoted market prices of comparable instruments or discounted cash flow analyses, incorporating inputs that are currently observable in the markets for similar securities. Inputs that are often used in the valuation methodologies include, but are not limited to, benchmark yields, credit spreads, default rates, prepayment speeds and non-binding broker quotes. As the Company is responsible for the determination of fair value, it performs quarterly analyses on the prices received from the pricing service to determine whether the prices are reasonable estimates of fair value. Specifically, the Company compares the prices received from the pricing service to a secondary pricing source, prices reported by its custodian, its investment consultant and third-party investment advisors. Additionally, the Company compares changes in the reported market values and returns to relevant market indices to test the reasonableness of the reported prices. The Company's internal price verification procedures and review of fair value methodology documentation provided by independent pricing services have not historically resulted in adjustment in the prices obtained from the pricing service.

Fair values of debt securities that do not trade on a regular basis in active markets but are priced using other observable inputs are classified as Level 2. The Company's Level 3 debt securities consist mainly of low income housing investments that are unique and non-transferable. The fair values of the Company's Level 3 debt securities are based on discounted cash flows from the investments.

Fair value estimates for Level 1 and Level 2 equity securities are based on quoted market prices for actively traded equity securities and/or other market data for the same or comparable instruments and transactions in establishing the prices.

The Company's Level 3 equity securities are primarily investments in venture capital securities. The fair values of Level 3 investments in venture capital portfolios are estimated using a market valuation technique that relies heavily on management assumptions and qualitative observations. Under the market approach, the fair values of the Company's various venture capital investments are computed using limited quantitative and qualitative observations of activity for similar companies in the current market. The Company's market modeling utilizes, as applicable, transactions for comparable companies in similar

industries and having similar revenue and growth characteristics; and similar preferences in their capital structure. Key significant unobservable inputs in the market technique include implied earnings before interest, taxes, depreciation and amortization (EBITDA) multiples and revenue multiples. Additionally, the fair value of certain of the Company's venture capital securities are based off of recent transactions in inactive markets for identical or similar securities. Significant changes in any of these inputs could result in significantly lower or higher fair value measurements.

Throughout the procedures discussed above in relation to the Company's processes for validating third party pricing information, the Company validates the understanding of assumptions and inputs used in security pricing and determines the proper classification in the hierarchy based on that understanding.

**AARP Program-related Investments.** AARP Program-related investments consist of debt and equity securities held to fund costs associated with the AARP Program and are priced and classified using the same methodologies as the Company's other securities.

**Interest Rate Swaps.** Fair values of the Company's interest rate swaps are estimated using the terms of the swaps and publicly available market yield curves. Because the swaps are unique and not actively traded, the fair values are classified as Level 2.

**Senior Unsecured Notes.** The fair values of the senior unsecured notes are estimated and classified using the same methodologies as the Company's investments in debt securities.

**AARP Program-related Other Liabilities.** AARP Program-related other liabilities consist of liabilities that represent the amount of net investment gains and losses related to AARP Program-related investments that accrue to the benefit of the AARP policyholders.

The following table presents a summary of fair value measurements by level for assets and liabilities measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets excluding AARP related assets and liabilities, which are discussed below:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair Value	Total Carrying Value
<b>March 31, 2012</b>					
Cash and cash equivalents.....	\$ 10,111	\$ 1,550	\$ —	\$ 11,661	\$ 11,661
Debt securities - available-for-sale:					
U.S. government and agency obligations.....	1,700	870	—	2,570	2,570
State and municipal obligations.....	—	6,496	—	6,496	6,496
Corporate obligations.....	19	6,169	—	6,188	6,188
U.S. agency mortgage-backed securities.....	—	2,387	—	2,387	2,387
Non-U.S. agency mortgage-backed securities....	—	486	7	493	493
Total debt securities - available-for-sale.....	1,719	16,408	7	18,134	18,134
Equity securities - available-for-sale.....	371	2	204	577	577
Total assets at fair value.....	<u>\$ 12,201</u>	<u>\$ 17,960</u>	<u>\$ 211</u>	<u>\$ 30,372</u>	<u>N/A</u>
Percentage of total assets at fair value.....	<u>40%</u>	<u>59%</u>	<u>1%</u>	<u>100%</u>	<u>N/A</u>
Interest rate swap liabilities.....	<u>\$ —</u>	<u>\$ 10</u>	<u>\$ —</u>	<u>\$ 10</u>	<u>\$ 10</u>
<b>December 31, 2011</b>					
Cash and cash equivalents.....	\$ 8,569	\$ 860	\$ —	\$ 9,429	\$ 9,429
Debt securities - available-for-sale:					
U.S. government and agency obligations.....	1,551	822	—	2,373	2,373
State and municipal obligations.....	—	6,750	15	6,765	6,765
Corporate obligations.....	16	5,805	186	6,007	6,007
U.S. agency mortgage-backed securities.....	—	2,353	—	2,353	2,353
Non-U.S. agency mortgage-backed securities....	—	497	7	504	504
Total debt securities - available-for-sale.....	1,567	16,227	208	18,002	18,002
Equity securities - available-for-sale.....	333	2	209	544	544
Total assets at fair value.....	<u>\$ 10,469</u>	<u>\$ 17,089</u>	<u>\$ 417</u>	<u>\$ 27,975</u>	<u>N/A</u>
Percentage of total assets at fair value.....	<u>37%</u>	<u>61%</u>	<u>2%</u>	<u>100%</u>	<u>N/A</u>

The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets for which it is practicable to estimate fair value:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair Value	Total Carrying Value
<b>March 31, 2012</b>					
Debt securities - held-to-maturity:					
U.S. government and agency obligations.....	\$ 177	\$ —	\$ —	\$ 177	\$ 171
State and municipal obligations .....	—	2	31	33	33
Corporate obligations .....	9	12	218	239	242
Total debt securities - held-to-maturity .....	<u>\$ 186</u>	<u>\$ 14</u>	<u>\$ 249</u>	<u>\$ 449</u>	<u>\$ 446</u>
Senior unsecured notes .....	<u>\$ —</u>	<u>\$ 14,037</u>	<u>\$ —</u>	<u>\$ 14,037</u>	<u>\$ 12,609</u>
<b>December 31, 2011</b>					
Debt securities - held-to-maturity:					
U.S. government and agency obligations.....	\$ 173	\$ —	\$ —	\$ 173	\$ 166
State and municipal obligations .....	—	1	12	13	13
Corporate obligations .....	9	9	—	18	18
Total debt securities - held-to-maturity .....	<u>\$ 182</u>	<u>\$ 10</u>	<u>\$ 12</u>	<u>\$ 204</u>	<u>\$ 197</u>
Senior unsecured notes .....	<u>\$ —</u>	<u>\$ 13,149</u>	<u>\$ —</u>	<u>\$ 13,149</u>	<u>\$ 11,638</u>

The carrying amounts reported in the Condensed Consolidated Balance Sheets for accounts and other current receivables, unearned revenues, commercial paper, accounts payable and accrued liabilities approximate fair value because of their short-term nature. These assets and liabilities are not listed in the table above.

A reconciliation of the beginning and ending balances of assets measured at fair value on a recurring basis using Level 3 inputs is as follows:

(in millions)	March 31, 2012			March 31, 2011		
	Debt Securities	Equity Securities	Total	Debt Securities	Equity Securities	Total
Balance at beginning of period.....	\$ 208	\$ 209	\$ 417	\$ 141	\$ 208	\$ 349
Purchases.....	—	18	18	—	4	4
Sales.....	—	(2)	(2)	—	(9)	(9)
Settlements.....	—	—	—	(6)	—	(6)
Net unrealized losses in accumulated other comprehensive income.....	—	—	—	—	(2)	(2)
Transfers to held-to-maturity.....	(201)	(21)	(222)	—	—	—
Balance at end of period.....	<u>\$ 7</u>	<u>\$ 204</u>	<u>\$ 211</u>	<u>\$ 135</u>	<u>\$ 201</u>	<u>\$ 336</u>

The following table presents quantitative information regarding unobservable inputs that were significant to the valuation of assets measured at fair value on a recurring basis using Level 3 inputs:

(in millions)	Fair Value	Valuation Technique	Unobservable Input	Range	
				Low	High
<b>March 31, 2012</b>					
Equity securities - available-for-sale					
Venture capital portfolios.....	\$ 174	Market approach - comparable companies	Revenue multiple	1.0	10.0
			EBITDA multiple	8.0	10.0
	<u>30</u>	Market approach - recent transactions	Inactive market transactions	N/A	N/A
Total equity securities available-for-sale.....	<u>\$ 204</u>				

Also included in the Company's assets measured at fair value on a recurring basis using Level 3 inputs were \$7 million of available-for-sale debt securities at March 31, 2012, which were not significant.

Non-financial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. There were no significant fair value adjustments for these assets and liabilities recorded during the three months ended March 31, 2012 and 2011.

The Company provides health insurance products and services to members of AARP under a Supplemental Health Insurance Program (the AARP Program). The Company elected to measure the entirety of the AARP Assets Under Management at fair value pursuant to the fair value option. See Note 2 of Notes to the Consolidated Financial Statements in the Company's 2011 10-K for further detail on AARP. The following table presents fair value information about the AARP Program-related financial assets and liabilities:

(in millions)	Quoted Prices in Active Markets (Level 1)	Other Observable Inputs (Level 2)	Unobservable Inputs (Level 3)	Total Fair Value
<b>March 31, 2012</b>				
Cash and cash equivalents .....	\$ 93	\$ 6	\$ —	\$ 99
Debt securities:				
U.S. government and agency obligations .....	575	222	—	797
State and municipal obligations .....	—	24	—	24
Corporate obligations .....	—	1,054	—	1,054
U.S. agency mortgage-backed securities .....	—	442	—	442
Non-U.S. agency mortgage-backed securities .....	—	150	—	150
Total debt securities .....	<u>575</u>	<u>1,892</u>	<u>—</u>	<u>2,467</u>
Equity securities - available-for-sale .....	—	2	—	2
Total assets at fair value .....	<u>\$ 668</u>	<u>\$ 1,900</u>	<u>\$ —</u>	<u>\$ 2,568</u>
Other liabilities .....	<u>\$ 22</u>	<u>\$ 56</u>	<u>\$ —</u>	<u>\$ 78</u>
Total liabilities at fair value .....	<u>\$ 22</u>	<u>\$ 56</u>	<u>\$ —</u>	<u>\$ 78</u>
<b>December 31, 2011</b>				
Cash and cash equivalents .....	\$ 257	\$ 10	\$ —	\$ 267
Debt securities:				
U.S. government and agency obligations .....	566	214	—	780
State and municipal obligations .....	—	25	—	25
Corporate obligations .....	—	1,048	—	1,048
U.S. agency mortgage-backed securities .....	—	436	—	436
Non-U.S. agency mortgage-backed securities .....	—	150	—	150
Total debt securities .....	<u>566</u>	<u>1,873</u>	<u>—</u>	<u>2,439</u>
Equity securities - available-for-sale .....	—	2	—	2
Total assets at fair value .....	<u>\$ 823</u>	<u>\$ 1,885</u>	<u>\$ —</u>	<u>\$ 2,708</u>
Other liabilities .....	<u>\$ 27</u>	<u>\$ 49</u>	<u>\$ —</u>	<u>\$ 76</u>
Total liabilities at fair value .....	<u>\$ 27</u>	<u>\$ 49</u>	<u>\$ —</u>	<u>\$ 76</u>

#### 4. CMS Prepayments and Medicare Part D Pharmacy Benefits

##### *CMS Prepayments*

On March 30, 2012, the Company received approximately \$2.5 billion for its April monthly premium payment and approximately \$500 million for the Catastrophic Reinsurance and Low-Income Member Cost Sharing Subsidies (Subsidies) and drug discount from the Centers for Medicare & Medicaid Services (CMS). CMS generally pays on the first calendar day of the applicable month. If the first calendar day of the month falls on a weekend or a holiday, CMS has typically paid the Company on the last business day of the preceding calendar month. The Company recorded the premium payment as unearned revenues in both its Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Cash Flows. The treatment of the Subsidies and drug discount is described below.



### **Medicare Part D Pharmacy Benefits Contract**

The Condensed Consolidated Balance Sheets include the following amounts associated with the Medicare Part D program:

(in millions)	March 31, 2012			December 31, 2011		
	Subsidies	Drug Discount	Risk-Share	Subsidies	Drug Discount	Risk-Share
Other current receivables .....	\$ —	\$ 91	\$ 135	\$ —	\$ 509	\$ —
Other policy liabilities .....	902	304	—	70	649	170

The Subsidies and drug discount represent cost reimbursements under the Medicare Part D program. The Company is fully reimbursed by CMS for costs incurred for these contract elements and, accordingly, there is no insurance risk to the Company. Amounts received for these Subsidies are not reflected as premium revenues, but rather are accounted for as a reduction of receivables and/or increase in deposit liabilities. For the drug discount, the Company records a liability when amounts are received from CMS and a receivable when the Company bills the pharmaceutical manufacturers. Related cash flows are presented as customer funds administered within financing activities in the Condensed Consolidated Statements of Cash Flows.

Premiums from CMS are subject to risk-sharing provisions based on a comparison of the Company's annual bid estimates of prescription drug costs and the actual costs incurred. Variances may result in CMS making additional payments to the Company or require the Company to remit funds to CMS subsequent to the end of the year. The Company records risk-share adjustments to premium revenue and other current receivables or other policy liabilities in the Condensed Consolidated Balance Sheets.

### **5. Medical Costs and Medical Costs Payable**

For the three months ended March 31, 2012, there was \$530 million of net favorable medical cost development related to prior fiscal years. The favorable development in 2012 was driven by lower than expected health system utilization levels and other factors that were individually immaterial.

For the three months ended March 31, 2011, there was \$440 million of net favorable medical cost development related to prior fiscal years. The favorable development in 2011 was primarily driven by lower than expected health system utilization levels and continued improvements in claims submission timeliness, which results in higher completion factors.

## 6. Commercial Paper and Long-Term Debt

Commercial paper and long-term debt consisted of the following:

(in millions)	March 31, 2012			December 31, 2011		
	Par Value	Carrying Value	Fair Value	Par Value	Carrying Value	Fair Value
Commercial paper .....	\$ 245	\$ 245	\$ 245	\$ —	\$ —	\$ —
5.500% senior unsecured notes due November 2012 ..	352	360	363	352	363	366
4.875% senior unsecured notes due February 2013 .....	534	538	553	534	540	556
4.875% senior unsecured notes due April 2013 .....	409	418	426	409	421	427
4.750% senior unsecured notes due February 2014 .....	172	183	184	172	184	185
5.000% senior unsecured notes due August 2014 .....	389	420	426	389	423	424
4.875% senior unsecured notes due March 2015 .....	416	455	459	416	458	460
5.375% senior unsecured notes due March 2016 .....	601	673	686	601	678	689
1.875% senior unsecured notes due November 2016 ..	400	397	404	400	397	400
5.360% senior unsecured notes due November 2016 ..	95	95	110	95	95	110
6.000% senior unsecured notes due June 2017 .....	441	497	530	441	499	518
6.000% senior unsecured notes due November 2017 ..	156	173	189	156	173	183
6.000% senior unsecured notes due February 2018 .....	1,100	1,122	1,329	1,100	1,123	1,308
3.875% senior unsecured notes due October 2020 .....	450	442	475	450	442	478
4.700% senior unsecured notes due February 2021 .....	400	419	449	400	419	450
3.375% senior unsecured notes due November 2021 ..	500	487	513	500	497	517
2.875% senior unsecured notes due March 2022 .....	600	596	587	—	—	—
Zero coupon senior unsecured notes due November 2022 .....	1,095	628	737	1,095	619	696
5.800% senior unsecured notes due March 2036 .....	850	844	978	850	844	1,017
6.500% senior unsecured notes due June 2037 .....	500	495	616	500	495	636
6.625% senior unsecured notes due November 2037 ..	650	645	822	650	645	834
6.875% senior unsecured notes due February 2038 .....	1,100	1,084	1,443	1,100	1,084	1,475
5.700% senior unsecured notes due October 2040 .....	300	298	348	300	298	359
5.950% senior unsecured notes due February 2041 .....	350	348	424	350	348	430
4.625% senior unsecured notes due November 2041 ..	600	593	600	600	593	631
4.375% senior unsecured notes due March 2042 .....	400	399	386	—	—	—
Total commercial paper and long-term debt.....	<u>\$ 13,105</u>	<u>\$ 12,854</u>	<u>\$ 14,282</u>	<u>\$ 11,860</u>	<u>\$ 11,638</u>	<u>\$ 13,149</u>

### **Commercial Paper and Bank Credit Facility**

Commercial paper consists of short-duration, senior unsecured debt privately placed on a discount basis through broker-dealers. As of March 31, 2012, the Company's outstanding commercial paper had a weighted-average annual interest rate of 0.5%.

The Company has a \$3.0 billion five-year revolving bank credit facility with 21 banks, which will mature in December 2016. This facility supports the Company's commercial paper program and is available for general corporate purposes. There were no amounts outstanding under this facility as of March 31, 2012. The interest rate on borrowings is variable based on term and amount and is calculated based on the London Interbank Offered Rate (LIBOR) plus a credit spread based on the Company's senior unsecured credit ratings. As of March 31, 2012, the annual interest rate on this facility, had it been drawn, would have ranged from 1.1% to 1.6%.

### **Debt Covenants**

The Company's bank credit facility contains various covenants including requiring the Company to maintain a debt-to-total-

capital ratio, calculated as debt divided by the sum of debt and shareholders' equity, below 50%. The Company was in compliance with its debt covenants as of March 31, 2012.

### ***Interest Rate Swap Contracts***

In March 2012, the Company entered into interest rate swap contracts to convert a portion of its interest rate exposure from fixed rates to floating rates to more closely align interest expense with interest income received on its cash equivalent and investment balances. The floating rates are benchmarked to LIBOR. The swaps are designated as fair value hedges on the Company's fixed-rate debt issue maturing November 2021 and have a notional amount of \$500 million. Since the critical terms of the swaps match those of the debt being hedged, they are assumed to be highly effective hedges and all changes in fair value of the swaps are recorded on the Condensed Consolidated Balance Sheets with no net impact recorded in the Condensed Consolidated Statements of Operations.

## **7. Share-Based Compensation**

As of March 31, 2012, the Company had 45 million shares available for future grants of share-based awards under its share-based compensation plan, including, but not limited to, incentive or non-qualified stock options, stock appreciation rights (SARs) and up to 17 million of awards in restricted stock and restricted stock units (restricted shares). The Company's outstanding share-based awards consist mainly of non-qualified stock options, SARs and restricted shares.

### ***Stock Options and SARs***

Stock options and SARs vest ratably over four to six years and may be exercised up to 10 years from the date of grant. Stock option and SAR activity for the three months ended March 31, 2012 is summarized in the table below:

	Shares (in millions)	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Life (in years)	Aggregate Intrinsic Value (in millions)
Outstanding at beginning of period .....	91	\$ 42		
Exercised .....	(11)	36		
Forfeited .....	(1)	44		
Outstanding at end of period .....	79	43	4.5	\$ 1,266
Exercisable at end of period .....	67	45	4.1	974
Vested and expected to vest end of period.....	78	43	4.5	1,254

For the three months ended March 31, 2012, the Company granted 94,000 stock options and SARs at a weighted-average exercise price of \$52.

### ***Restricted Shares***

Restricted shares vest ratably over three to four years. Compensation expense related to restricted shares is based on the share price on date of grant. Restricted share activity for the three months ended March 31, 2012 is summarized in the table below:

(shares in millions)	Shares	Weighted- Average Grant Date Fair Value per Share
Nonvested at beginning of period .....	17	\$ 36
Granted .....	6	52
Vested.....	(6)	34
Nonvested at end of period .....	17	43

## Other Share-Based Compensation Data

(in millions, except per share amounts)	Three Months Ended March 31,	
	2012	2011
<b>Stock Options and SARs</b>		
Weighted-average grant date fair value of shares granted, per share.....	\$ 18	\$ 15
Total intrinsic value of stock options and SARs exercised.....	220	67
<b>Restricted Shares</b>		
Weighted-average grant date fair value of shares granted, per share.....	52	42
Total fair value of restricted shares vested.....	291	69
<b>Share-Based Compensation Items</b>		
Share-based compensation expense, before tax.....	140	123
Share-based compensation expense, net of tax effects.....	88	84
Income tax benefit realized from share-based award exercises.....	187	57

(in millions, except years)	March 31, 2012
Unrecognized compensation expense related to share awards.....	\$ 523
Weighted-average years to recognize compensation expense.....	1.1

### Share-Based Compensation Recognition

The Company recognizes compensation expense for share-based awards, including stock options, SARs and restricted shares, on a straight-line basis over the related service period (generally the vesting period) of the award, or to an employee's eligible retirement date under the award agreement, if earlier. Share-based compensation expense is recognized in operating costs in the Company's Condensed Consolidated Statements of Operations.

To determine compensation expense related to the Company's stock options and SARs, the fair value of each award is estimated on the date of grant using a binomial option-pricing model. The principal assumptions the Company used in applying the option-pricing model were as follows:

	Three Months Ended March 31,	
	2012	2011
Risk free interest rate.....	0.9%	2.3%
Expected volatility.....	43.4%	44.3%
Expected dividend yield.....	1.3%	1.2%
Forfeiture rate.....	5.0%	5.0%
Expected life in years.....	5.3 - 5.6	4.9

Risk-free interest rates are based on U.S. Treasury yields in effect at the time of grant. Expected volatilities are based on the historical volatility of the Company's common stock and the implied volatility from exchange-traded options on the Company's common stock. Expected dividend yields are based on the per share dividend declared by the Company's Board of Directors. The Company uses historical data to estimate option and SAR exercises and forfeitures within the valuation model. The expected lives of options and SARs granted represents the period of time that the awards granted are expected to be outstanding based on historical exercise patterns.

## 8. Commitments and Contingencies

### Legal Matters

Because of the nature of its businesses, the Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, providers, customers and regulators, relating to the Company's management and administration of health benefit plans. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims, and claims related to health care benefits coverage and other business practices.

The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of

probable costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable that a loss may be incurred.

### ***Litigation Matters***

***Out-of-Network Reimbursement Litigation.*** In 2000, a group of plaintiffs including the American Medical Association filed a lawsuit against the Company asserting a variety of claims challenging the Company's determination of reimbursement amounts for non-network health care services based on the Company's use of a database previously maintained by Ingenix, Inc. (now known as OptumInsight). The parties entered into a settlement agreement in 2009 and this class action lawsuit, along with a related industry-wide investigation by the New York Attorney General, is now resolved. The Company remains a party to a number of other lawsuits challenging the determination of out of network reimbursement amounts based on use of the same database, including putative class actions and multidistrict litigation brought on behalf of members of Aetna and WellPoint. The Company was dismissed as a party from a similar lawsuit involving Cigna and its members. These suits allege, among other things, that the database licensed to these companies by Ingenix was flawed and that Ingenix conspired with these companies to underpay their members' claims and seek unspecified damages and treble damages, injunctive and declaratory relief, interest, costs and attorneys fees. The Company is vigorously defending these suits. The Company cannot reasonably estimate the range of loss, if any, that may result from these matters due to the procedural status of the cases, motions to dismiss that are pending in several of the cases, the absence of class certification in any of the cases, the lack of a formal demand on the Company by the plaintiffs, and the involvement of other insurance companies as defendants.

***California Claims Processing Matter.*** In 2007, the California Department of Insurance (CDI) examined the Company's PacifiCare health insurance plan in California. The examination findings related to the timeliness and accuracy of claims processing, interest payments, provider contract implementation, provider dispute resolution and other related matters. On January 25, 2008, the CDI issued an Order to Show Cause to PacifiCare Life and Health Insurance Company, a subsidiary of the Company, alleging violations of certain insurance statutes and regulations in connection with the CDI's examination findings. On June 3, 2009, the Company filed a Notice of Defense to the Order to Show Cause denying all material allegations and asserting certain defenses. The matter has been the subject of an administrative hearing before a California administrative law judge since December 2009. CDI amended its Order to Show Cause three times in 2010 to allege a total of 992,936 violations, the large majority of which relate to an alleged failure to include certain language in standard claims correspondence during a four month period in 2007. Although we believe that CDI has never issued an aggregate penalty in excess of \$8 million, CDI has previously alleged in press reports and releases that the Company could theoretically be subject to penalties of up to \$10,000 per violation. In October 2011, CDI stated that it is seeking an average penalty of approximately \$326 per alleged violation. CDI has since reduced the number of alleged violations to 919,574 but has indicated that it is still seeking an aggregate penalty of approximately \$325 million. The Company is vigorously defending against the claims in this matter and believes that the penalty requested by CDI is excessive and without merit. After the administrative law judge issues a ruling at the conclusion of the administrative proceeding, expected no earlier than November 2012, the California Insurance Commissioner may accept, reject or modify the administrative law judge's ruling, issue his own decision, and impose a fine or penalty. The Commissioner's decision is subject to challenge in court. The Company cannot reasonably estimate the range of loss, if any, that may result from this matter given the procedural status of the dispute, the novel legal issues presented (including the legal basis for the majority of the alleged violations), the inherent difficulty in predicting regulatory fines and penalties, and the various remedies and levels of judicial review available to the Company in the event a fine or penalty is assessed.

### ***Government Regulation***

The Company's business is regulated at federal, state, local and international levels. The laws and rules governing the Company's business and interpretations of those laws and rules are subject to frequent change. Broad latitude is given to the agencies administering those regulations. Further, the Company must obtain and maintain regulatory approvals to market and sell many of its products.

The Company has been and is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by CMS, state insurance and health and welfare departments, state attorneys general, the Office of Inspector General (OIG), the Office of Personnel Management, the Office of Civil Rights, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice, U.S. Attorneys, the SEC, the Internal Revenue Service (IRS), the U.S. Department of Labor (DOL), the Federal Deposit Insurance Corporation and other

governmental authorities. For example, in the fourth quarter of 2011, CMS conducted an audit of the Company's Medicare Advantage and Part D business. The Company is in the process of responding to preliminary findings. Other examples of audits include the risk adjustment data validation (RADV) audits discussed below and a review by the DOL of the Company's administration of applicable customer employee benefit plans with respect to the Employee Retirement Income Security Act of 1974, as amended (ERISA) compliance.

Government actions can result in assessment of damages, civil or criminal fines or penalties, or other sanctions, including loss of licensure or exclusion from participation in government programs and could have a material adverse effect on the Company's results of operations, financial position and cash flows.

**Risk Adjustment Data Validation Audits.** CMS adjusts capitation payments to Medicare Advantage plans and Medicare Part D plans according to the predicted health status of each beneficiary as supported by data from health care providers. The Company collects claim and encounter data from providers, who the Company generally relies on to appropriately code their claim submissions and document their medical records. CMS then determines the risk score and payment amount for each enrolled member based on the health care data submitted and member demographic information.

In 2008, CMS announced that it would perform RADV audits of selected Medicare Advantage health plans each year to validate the coding practices of and supporting documentation maintained by health care providers. These audits involve a review of medical records maintained by providers and may result in retrospective adjustments to payments made to health plans.

In February 2012, CMS announced a revised, final RADV audit and payment adjustment methodology. Under the final methodology, CMS will conduct RADV audits beginning with the 2011 payment year. CMS has not communicated how the final payment adjustment under its methodology will be implemented, nor has the Company been notified of specific health plans that will be selected for audit. Accordingly, the Company cannot reasonably estimate the range of loss, if any, that may result from future RADV audits. However, potential payment adjustments could have a material adverse effect on the Company's results of operations, financial position and cash flows.

The OIG for the U.S. Department of Health and Human Services (HHS) has audited the Company's risk adjustment data for two local plans and has initially communicated its findings. While the Company does not believe OIG has governing authority to directly impose payment adjustments for risk adjustment audits of Medicare health plans operated under the regulatory authority of CMS, the OIG can recommend to CMS a proposed payment adjustment. The Company is unable to predict the ultimate outcome of this audit process.

**Guaranty Fund Assessments.** Under state guaranty assessment laws, certain insurance companies (and health maintenance organizations in some states), including those issuing health (which includes long-term care), life and accident insurance policies, doing business in those states can be assessed (up to prescribed limits) for certain obligations to the policyholders and claimants of insolvent insurance companies that write the same line or lines of business. Assessments are generally based on premiums in the state compared to the premiums of other insurers, and could be spread out over a period of years. Some states permit member insurers to recover assessments paid through full or partial premium tax offsets.

The Pennsylvania Insurance Commissioner has placed Penn Treaty Network America Insurance Company and its subsidiary (Penn Treaty), neither of which are affiliated with the Company, in rehabilitation, an intermediate action before insolvency, and has petitioned a state court for liquidation. If Penn Treaty is liquidated, the Company's insurance entities and other insurers may be required to pay a portion of Penn Treaty's policyholder claims through guaranty association assessments in future periods. The Company estimates a potential assessment of \$350 million to \$450 million related to this matter, and the Company would accrue the assessment in operating costs if and when the state court renders such a decision. The timing, actual amount and impact, if any, of any guaranty fund assessments will depend on several factors, including if and when the court declares Penn Treaty insolvent, the amount of the insolvency, the availability and amount of any potential offsets, such as an offset of any premium taxes otherwise payable by the Company, and the impact of any such assessments on potential premium rebate payments under Health Reform Legislation.

## **9. Segment Financial Information**

Factors used to determine the Company's reportable segments include the nature of operating activities, economic characteristics, existence of separate senior management teams and the type of information presented to the Company's chief operating decision maker to evaluate its results of operations. Reportable segments with similar economic characteristics are combined.

The following is a description of the types of products and services from which each of the Company's four reportable segments derives its revenues:

- *UnitedHealthcare* includes the combined results of operations of UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State because they have similar economic characteristics, products and services, customers, distribution methods and operational processes and operate in a similar regulatory environment. These businesses also share significant common assets, including a contracted network of physicians, health care professionals, hospitals and other facilities, information technology infrastructure and other resources. UnitedHealthcare Employer & Individual offers an array of consumer-oriented health benefit plans and services for large national employers, public sector employers, mid-sized employers, small businesses and individuals nationwide. UnitedHealthcare Medicare & Retirement provides health and well-being services to individuals age 50 and older, addressing their unique needs for preventive and acute health care services as well as services dealing with chronic disease and other specialized issues for older individuals. UnitedHealthcare Community & State provides health plans and care programs to beneficiaries of acute and long-term care Medicaid plans, the Children's Health Insurance Program (CHIP), Special Needs Plans and other federal and state health care programs.
- *OptumHealth* serves the physical, emotional and financial needs of individuals, enabling consumer health management and collaborative care delivery through programs offered by employers, payers, government entities and directly with the care delivery system. OptumHealth offers personalized health management services, decision support services, access to networks of care provider specialists, well-being solutions, behavioral health management solutions, financial services and clinical services.
- *OptumInsight* is a health information, technology, services and consulting company providing software and information products, advisory consulting services, and business process outsourcing to participants in the health care industry. Hospitals, physicians, commercial health plans, government agencies, life sciences companies and other organizations within the health care system work with OptumInsight to reduce costs, meet compliance mandates, improve clinical performance and adapt to the changing health system landscape.
- *OptumRx* offers a multitude of pharmacy benefit management services including providing prescribed medications, patient support and clinical programs. OptumRx also provides claims processing, retail network contracting, rebate contracting and management and clinical programs, such as step therapy, formulary management and disease/drug therapy management programs to achieve a low-cost, high-quality pharmacy benefit.

Transactions between reportable segments principally consist of sales of pharmacy benefit products and services to UnitedHealthcare customers by OptumRx, certain product offerings and clinical services sold to UnitedHealthcare by OptumHealth, and health information and technology solutions, consulting and other services sold to UnitedHealthcare by OptumInsight. These transactions are recorded at management's estimate of fair value. Intersegment transactions are eliminated in consolidation.

Corporate and intersegment elimination amounts are presented to reconcile the reportable segment results to the consolidated results. The following table presents reportable segment financial information:

(in millions)	UnitedHealthcare	Optum				Corporate and Intersegment Eliminations	Consolidated
		OptumHealth	OptumInsight	OptumRx	Total Optum		
<b>Three Months Ended March 31, 2012</b>							
Revenues - external customers:							
Premiums .....	\$ 24,211	\$ 420	\$ —	\$ —	\$ 420	\$ —	\$ 24,631
Services .....	1,178	202	390	21	613	—	1,791
Products .....	—	7	17	664	688	—	688
Total revenues - external customers..	<u>25,389</u>	<u>629</u>	<u>407</u>	<u>685</u>	<u>1,721</u>	<u>—</u>	<u>27,110</u>
Total revenues - intersegment .....	—	1,282	264	4,036	5,582	(5,582)	—
Investment and other income .....	144	28	—	—	28	—	172
Total revenues .....	<u>\$ 25,533</u>	<u>\$ 1,939</u>	<u>\$ 671</u>	<u>\$ 4,721</u>	<u>\$ 7,331</u>	<u>\$ (5,582)</u>	<u>\$ 27,282</u>
Earnings from operations .....	<u>\$ 2,065</u>	<u>\$ 92</u>	<u>\$ 89</u>	<u>\$ 71</u>	<u>\$ 252</u>	<u>\$ —</u>	<u>\$ 2,317</u>
Interest expense .....	—	—	—	—	—	(148)	(148)
Earnings before income taxes .....	<u>\$ 2,065</u>	<u>\$ 92</u>	<u>\$ 89</u>	<u>\$ 71</u>	<u>\$ 252</u>	<u>\$ (148)</u>	<u>\$ 2,169</u>
<b>Three Months Ended March 31, 2011</b>							
Revenues - external customers:							
Premiums .....	\$ 22,656	\$ 347	\$ —	\$ —	\$ 347	\$ —	\$ 23,003
Services .....	1,056	87	436	19	542	—	1,598
Products .....	—	6	16	627	649	—	649
Total revenues - external customers..	<u>23,712</u>	<u>440</u>	<u>452</u>	<u>646</u>	<u>1,538</u>	<u>—</u>	<u>25,250</u>
Total revenues - intersegment .....	—	1,047	219	3,986	5,252	(5,252)	—
Investment and other income .....	162	20	—	—	20	—	182
Total revenues .....	<u>\$ 23,874</u>	<u>\$ 1,507</u>	<u>\$ 671</u>	<u>\$ 4,632</u>	<u>\$ 6,810</u>	<u>\$ (5,252)</u>	<u>\$ 25,432</u>
Earnings from operations .....	<u>\$ 1,899</u>	<u>\$ 109</u>	<u>\$ 83</u>	<u>\$ 130</u>	<u>\$ 322</u>	<u>\$ —</u>	<u>\$ 2,221</u>
Interest expense .....	—	—	—	—	—	(118)	(118)
Earnings before income taxes .....	<u>\$ 1,899</u>	<u>\$ 109</u>	<u>\$ 83</u>	<u>\$ 130</u>	<u>\$ 322</u>	<u>\$ (118)</u>	<u>\$ 2,103</u>



## **ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes. References to the terms "UnitedHealth Group," "we," "our" or "us" used throughout this Management's Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its subsidiaries.

### ***EXECUTIVE OVERVIEW***

#### **General**

UnitedHealth Group is a diversified health and well-being company dedicated to helping people live healthier lives and making health care work better. We offer a broad spectrum of products and services through two distinct platforms: UnitedHealthcare, which provides health care coverage and benefits services; and Optum, which provides information and technology-enabled health services.

#### **Business Trends**

Our businesses participate in the U.S. health economy, which comprises approximately 18% of U.S. gross domestic product and has grown consistently for many years. We expect overall spending on health care in the U.S. to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the U.S. population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macro-economic conditions and enacted health care reforms, which could also impact our results of operations.

In 2012, we expect increasing unit costs to continue to be the primary cost driver of medical cost trends and we project steadily increasing medical system utilization over the course of the year. We also expect an increase in prescription drug costs compared to 2011. We will continue to work to manage medical cost trends through care management programs, affordable network relationships, pay-for-performance reimbursement programs for care providers, and targeted clinical management programs and initiatives focused on improving quality and affordability. Additionally, employers are continuing to select products with benefit designs that shift more of the costs to the employee.

Care providers are facing market pressures to change from fee-for-service models to new delivery models focused on the holistic health of the consumer, integrated care across care providers and pay-for-performance payment structures. This is creating the need for health management services that can coordinate care around the primary care physician and for investment in new clinical and administrative information and management systems. We expect that the portion of our costs that is tied to incentive contracts that reward providers for outcome-based results and improved cost efficiencies will continue to increase, and we expect these trends to provide growth opportunities for our Optum business platform.

We seek to price our products consistent with anticipated underlying medical trends, while balancing growth, margins, competitive dynamics and premium rebates at the local market level. We work to sustain a stable medical care ratio for an equivalent mix of business. Changes in business mix, such as expanding participation in comparatively higher medical care ratio government-sponsored public sector programs and Health Reform Legislation may impact our premiums, medical costs and medical care ratio. In 2012, we continue to expect reimbursements to be under pressure through government payment rates and continued market competition in commercial products.

#### **Regulatory Trends and Uncertainties**

In the first quarter of 2010, the Health Reform Legislation was signed into law. The Health Reform Legislation expands access to coverage and modifies aspects of the commercial insurance market, the Medicaid and Medicare programs, CHIP and other aspects of the health care system. Although the HHS, DOL, IRS and the Treasury Department have issued or proposed regulations on a number of aspects of the Health Reform Legislation, final rules and interim guidance on other key aspects of the Health Reform Legislation, all of which have a variety of effective dates, remain pending.

Following is a summary of management's view of the trends and uncertainties related to some of the key provisions of the Health Reform Legislation and other regulatory items.

**Premium Rebates** - Effective in 2011, commercial health plans with medical loss ratios on fully insured products that fall below certain targets are required to rebate ratable portions of their premiums annually.

In response to the Health Reform Legislation, minimum loss ratios and premium rebates are considered in the pricing of our

products. We have also made changes to reduce our product distribution costs, including reducing producer commissions, and are continuing to implement changes to distribution in the large group insured market segment. Our results in 2012 and 2011 include the effects of our estimates of the premium rebates. First quarter 2012 results include the effects of updating estimates and regulatory clarifications regarding the calculations of 2011 premium rebates payable. The 2011 rebate is payable in the third quarter of 2012. Consistent with the prior year accounting, estimated 2012 rebates payable in 2013 are being recorded throughout 2012 as a reduction in premium revenue.

**Commercial Rate Increase Review** - The Health Reform Legislation also requires HHS to maintain an annual review of “unreasonable” increases in premium rates for commercial health plans. HHS established a review threshold of annual premium rate increases generally at or above 10% (with state-specific thresholds to be applicable commencing September 2012) and clarified that HHS review will not supersede existing state review and approval procedures. Premium rate review legislation (ranging from new or enhanced rate filing requirements to prior approval requirements) has been introduced or passed in more than half of the states as of the date of this report.

The competitive forces common in our markets do not support unjustifiable rate increases. We have experienced and expect to continue to experience throughout 2012 a tight, competitive commercial pricing environment. Further, our rates and rate filings are developed using methods consistent with the standards of actuarial practices. However, we have begun to experience greater regulatory challenges to appropriate premium rate increases in several states, including California, New York and Rhode Island. Depending on the level of scrutiny by the states, there is a broad range of potential business impacts. For example, it may become more difficult to price our commercial risk business consistent with expected underlying cost trends, leading to the risk of operating margin compression in the commercial health benefits business.

**Medicare Advantage Rates** - Beginning in 2012, additional cuts from 2011 to Medicare Advantage benchmarks have taken effect (benchmarks will ultimately range from 95% of Medicare fee-for-service rates in high cost areas to 115% in low cost areas), with changes being phased-in over two to six years, depending on the level of benchmark reduction in a county. Additionally, Congress passed the Budget Control Act of 2011, which following a failure of the Joint Select Committee on Deficit Reduction to cut the federal deficit by \$1.2 trillion, triggers automatic across-the-board budget cuts (sequestration), including Medicare spending cuts averaging 2% of total program costs for nine years, starting in 2013.

We expect the 2012 and 2013 Medicare Advantage rates will be outpaced by underlying medical trends, placing continued importance on effective medical management and ongoing improvements in administrative costs. There are a number of annual adjustments we can and are making to our operations, which may partially offset any impact from these rate reductions. For example, we seek to intensify our medical and operating cost management, adjust members' benefits and decide on a county-by-county basis in which geographies to participate. Additionally, achieving high quality scores from CMS for improving upon certain clinical and operational performance standards will impact future quality bonuses that may offset these anticipated rate reductions. Taken together, we expect a slight increase in Medicare Advantage medical care ratio in 2012.

We also may be able to mitigate the effects of reduced funding by increasing enrollment due to the increasing number of people eligible for Medicare in coming years. Compared to the first quarter of 2011, our Medicare Advantage membership has increased by 330,000 consumers or 15%, including XL Health Corporation. Longer term, market wide decreases in the availability or relative quality of Medicare Advantage products may increase demand for other senior health benefits products such as our Medicare Part D and Medicare Supplement insurance offerings.

**Industry Fees** - The Health Reform Legislation includes an annual, non-deductible insurance industry assessment to be levied proportionally across the insurance industry. The amount of the annual fee is \$8 billion in 2014, \$11.3 billion for 2015 and 2016, \$13.9 billion in 2017 and \$14.3 billion in 2018. For 2019 and beyond, the amount will be equal to the annual fee for the preceding year increased by the rate of premium growth for the preceding year. The annual fee will be allocated based on the ratio of an entity's net premiums written during the preceding calendar year to the total health insurance industry's net premiums written for any U.S. health risk during the preceding calendar year, subject to certain exceptions. This fee will be first paid and expensed in 2014. As a result of the non-deductibility of these fees, our effective income tax rate will increase significantly in 2014.

With the introduction of state health insurance exchanges in 2014, the Health Reform Legislation includes three programs designed to stabilize the health insurance markets. These programs are: a transitional Reinsurance Program; a temporary Risk Corridors Program; and a permanent Risk Adjustment Program. The transitional Reinsurance Program is a temporary program, which will be funded on a per capita basis from all commercial lines of business including insured and self-funded arrangements (\$25 billion over a three-year period beginning in 2014; \$20 billion (subject to increase based on state decisions) of which funds the state reinsurance pools and \$5 billion funds the U.S. Treasury). While the final HHS regulations have been released, the terms of the specific reinsurance programs to be used in each state are not yet known.

Premium increases will be necessary to offset the impact of these assessments, and other Health Reform Legislation provisions.

Premium increases are generally subject to state regulatory approval and potentially federal review.

***State-Based Exchanges and Coverage Expansion*** - Effective in 2014, state-based exchanges are required to be established for individuals and small employers. The Health Reform Legislation also provides for expanded Medicaid coverage effective in January 2014.

The Congressional Budget Office has estimated that up to 33 million additional individuals may eventually gain insurance coverage if the Health Reform Legislation is implemented broadly in its current form. This represents an opportunity for us to increase membership. However, serving these individuals may generate different profit margins than our existing business due to various factors, including the health status of the newly insured individuals.

We expect existing participants in Medicare and Medicaid and new enrollees in state-based exchanges to transition between products and programs, offering us opportunities to design products and services that enable us to compete for new business across business segments on an ongoing basis. We have created a national exchange strategy team to oversee readiness and implementation for exchanges across our organization.

***Court Proceedings and Congressional Action*** - Court proceedings related to the Health Reform Legislation continue to evolve. The United States Supreme Court heard oral arguments in March 2012 with the proponents of such challenges seeking to limit the scope of or have all or portions of the Health Reform Legislation declared unconstitutional. The Supreme Court may find all aspects of the law constitutional, may find the individual mandate unconstitutional and strike this provision and possibly any other provisions with a material connection to the mandate, strike down the whole law, or determine that the case is not yet ripe. Congress may withhold the funding necessary to implement the Health Reform Legislation, or may attempt to replace the legislation with amended provisions or repeal it altogether. Any partial or complete repeal or amendment, or uncertainty regarding such events, could materially and adversely impact our ability to capitalize on the opportunities presented by the Health Reform Legislation or may cause us to incur additional costs of compliance or reversing some of the changes we have already implemented. For example, if the individual mandate is declared unconstitutional or repealed without corresponding changes to other provisions of the Health Reform Legislation to protect against the risk of adverse selection (such as revisions to the guaranteed issue, prohibition on pre-existing condition exclusions, and rating restrictions), our results of operations, financial position and cash flows could be materially and adversely affected. The Supreme Court is scheduled to render a decision in late June. The pending Supreme Court proceeding, and the potential for Congressional action to impede implementation, create additional uncertainties with respect to the law including whether the law will be revoked.

For additional information regarding the Health Reform Legislation and Regulatory Trends and Uncertainties, see Item 1, "Business - Government Regulation," Item 1A, "Risk Factors" and Item 7, "Management's Discussion and Analysis of Financial Condition and Results of Operations - Regulatory Trends and Uncertainties" in our 2011 10-K.

## RESULTS SUMMARY

(in millions, except percentages and per share data)	Three Months Ended March 31,		Increase/(Decrease)	
	2012	2011	2012 vs. 2011	
Revenues:				
Premiums .....	\$ 24,631	\$ 23,003	\$ 1,628	7%
Services .....	1,791	1,598	193	12
Products .....	688	649	39	6
Investment and other income .....	172	182	(10)	(5)
Total revenues .....	<u>27,282</u>	<u>25,432</u>	<u>1,850</u>	7
Operating costs:				
Medical costs .....	19,939	18,725	1,214	6
Operating costs .....	4,096	3,617	479	13
Cost of products sold .....	634	599	35	6
Depreciation and amortization .....	296	270	26	10
Total operating costs .....	<u>24,965</u>	<u>23,211</u>	<u>1,754</u>	8
Earnings from operations .....	2,317	2,221	96	4
Interest expense .....	(148)	(118)	30	25
Earnings before income taxes .....	2,169	2,103	66	3
Provision for income taxes .....	(781)	(757)	24	3
Net earnings .....	<u>\$ 1,388</u>	<u>\$ 1,346</u>	<u>\$ 42</u>	3%
Diluted net earnings per common share .....	<u>\$ 1.31</u>	<u>\$ 1.22</u>	<u>\$ 0.09</u>	7%
Medical care ratio (a) .....	81.0%	81.4%	(0.4)%	
Operating cost ratio .....	15.0	14.2	0.8	
Operating margin .....	8.5	8.7	(0.2)	
Tax rate .....	36.0	36.0	—	
Net margin .....	5.1	5.3	(0.2)	
Return on equity (b) .....	19.4%	20.6%	(1.2)%	

(a) Medical care ratio is calculated as medical costs divided by premium revenue.

(b) Return on equity is calculated as annualized net earnings divided by average equity. Average equity is calculated using the equity balance at the end of the preceding year and the equity balances at the end of each of the quarters in the periods presented.

### SELECTED OPERATING PERFORMANCE AND FINANCIAL LIQUIDITY ITEMS

The following represents a summary of selected first quarter 2012 year-over-year operating comparisons to first quarter 2011 and liquidity items.

- Consolidated total revenues of \$27 billion increased 7%.
- UnitedHealthcare revenues of \$26 billion rose 7%.
- Optum revenues of \$7 billion increased 8%.
- UnitedHealthcare medical enrollment during 2012 grew by 1.6 million people; Medicare Part D stand-alone membership decreased by 0.5 million people.
- Consolidated medical care ratio of 81.0% decreased 40 basis points.
- Net earnings of \$1.4 billion and diluted earnings per share of \$1.31 increased 3% and 7%, respectively.
- Liquidity:
  - \$1.1 billion in cash was held by non-regulated entities as of March 31, 2012.
  - 2012 debt offering raised new debt totaling \$1.0 billion.
  - Debt to debt-plus-equity ratio increased 170 basis points to 30.8% from 29.1% as of December 31, 2011.
  - Cash paid for acquisitions in 2012, net of cash assumed, totaled \$1.9 billion.

## ***FIRST QUARTER 2012 RESULTS OF OPERATIONS COMPARED TO FIRST QUARTER 2011 RESULTS***

### **Consolidated Financial Results**

#### ***Revenues***

The increases in revenues for the three months ended March 31, 2012 were driven by growth in the number of individuals served and commercial premium rate increases reflecting expected underlying medical cost trends in our UnitedHealthcare businesses and overall growth at OptumHealth.

#### ***Medical Costs***

Medical costs for the three months ended March 31, 2012 increased due to risk-based membership growth in our public and senior markets businesses and continued increases in the cost per service paid for health system use, partially offset by an increase in net favorable medical cost development. Unit cost increases represented the majority of the increases in our medical cost trend, with the largest contributor being price increases to hospitals.

For each period, our operating results include the effects of revisions in medical cost estimates related to prior periods. Changes in medical cost estimates related to prior periods, resulting from more complete claim information identified in the current period, are included in total medical costs reported for the current period. For the three months ended March 31, 2012 and 2011 there was \$530 million and \$440 million, respectively, of net favorable medical cost development related to prior fiscal years. The favorable development in 2012 was driven by lower than expected health system utilization levels in 2011 and other factors that were individually immaterial. The favorable development in 2011 was primarily driven by continued improvements in claims submission timeliness, which resulted in higher completion factors and lower than expected health system utilization levels in 2010.

#### ***Operating Costs***

The increase in our operating costs for the three months ended March 31, 2012 was due to business growth, including an increase in fee-based benefits and fee-based service revenues, which carry comparatively higher operating costs as well as investments in the pharmacy management services business.

### **Reportable Segments**

We have four reportable segments across our two business platforms, UnitedHealthcare and Optum:

- UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State;
- OptumHealth;
- OptumInsight; and
- OptumRx.

See Note 9 of Notes to the Condensed Consolidated Financial Statements and Item 1, "Business" in our 2011 10-K for a description of how each of our reportable segments derives its revenues.

Transactions between reportable segments principally consist of sales of pharmacy benefit products and services to UnitedHealthcare customers by OptumRx, certain product offerings and clinical services sold to UnitedHealthcare by OptumHealth, and health information and technology solutions, consulting and other services sold to UnitedHealthcare by OptumInsight. These transactions are recorded at management's estimate of fair value. Intersegment transactions are eliminated in consolidation.

The following table presents reportable segment financial information:

(in millions, except percentages)	Three Months Ended March 31,		Increase/(Decrease)	
	2012	2011	2012 vs. 2011	
<b>Revenues</b>				
UnitedHealthcare .....	\$ 25,533	\$ 23,874	\$ 1,659	7%
OptumHealth .....	1,939	1,507	432	29
OptumInsight .....	671	671	—	—
OptumRx .....	4,721	4,632	89	2
Total Optum.....	7,331	6,810	521	8
Eliminations.....	(5,582)	(5,252)	330	nm
Consolidated revenues.....	<u>\$ 27,282</u>	<u>\$ 25,432</u>	<u>\$ 1,850</u>	7%
<b>Earnings from operations</b>				
UnitedHealthcare .....	\$ 2,065	\$ 1,899	\$ 166	9%
OptumHealth .....	92	109	(17)	(16)
OptumInsight .....	89	83	6	7
OptumRx .....	71	130	(59)	(45)
Total Optum.....	252	322	(70)	(22)
Consolidated earnings from operations .....	<u>\$ 2,317</u>	<u>\$ 2,221</u>	<u>\$ 96</u>	4%
<b>Operating margin</b>				
UnitedHealthcare .....	8.1%	8.0%	0.1 %	
OptumHealth .....	4.7	7.2	(2.5)	
OptumInsight .....	13.3	12.4	0.9	
OptumRx .....	1.5	2.8	(1.3)	
Total Optum.....	3.4	4.7	(1.3)	
Consolidated operating margin.....	8.5%	8.7%	(0.2)%	

nm = not meaningful

### **UnitedHealthcare**

The following table summarizes UnitedHealthcare revenue by business:

(in billions, except percentages)	Three Months Ended March 31,		Increase/(Decrease)	
	2012	2011	2012 vs. 2011	
UnitedHealthcare Employer & Individual.....	\$ 11.7	\$ 11.2	\$ 0.5	4%
UnitedHealthcare Medicare & Retirement .....	10.2	9.4	0.8	9
UnitedHealthcare Community & State.....	3.6	3.3	0.3	9
Total UnitedHealthcare revenue.....	<u>\$ 25.5</u>	<u>\$ 23.9</u>	<u>\$ 1.6</u>	7%

The following table summarizes the number of individuals served by our UnitedHealthcare businesses, by major market segment and funding arrangement:

(in thousands, except percentages)	Three Months Ended March 31,		Increase/(Decrease)	
	2012	2011	2012 vs. 2011	
Commercial risk-based.....	9,360	9,470	(110)	(1)%
Commercial fee-based.....	17,085	16,130	955	6
Total commercial.....	26,445	25,600	845	3
Medicare Advantage.....	2,495	2,165	330	15
Medicaid.....	3,590	3,390	200	6
Medicare Supplement.....	3,040	2,840	200	7
Total public and senior.....	9,125	8,395	730	9
Total UnitedHealthcare - medical.....	35,570	33,995	1,575	5 %
Supplemental Data:				
Medicare Part D stand-alone.....	4,240	4,745	(505)	(11)%

UnitedHealthcare's year-over-year membership growth was balanced and diversified with just over one-half in the commercial markets and the remainder in the public and senior markets. Commercial risk-based membership decreased primarily due to a combination of conversions to fee-based products by large public sector clients that we retained and other decreases in the public sector. In fee-based commercial products the increase was due to strong retention and a solid 2012 selling season. Medicare Advantage increased due to strengthened execution in product design, marketing and local engagement combined with the addition of 120,000 Medicare Advantage members from the acquisition of XL Health Corporation in February 2012. Medicaid growth was due to a combination of winning new state accounts and growth within existing state customers. Medicare Supplement growth was due to strong retention and new sales. In our Medicare Part D stand-alone business, membership decreased by 505,000 people year-over-year including 615,000 people in the first quarter, primarily as a result of the first quarter 2012 loss of approximately 470,000 of our auto-assigned low-income subsidy Medicare Part D beneficiaries, mainly due to pricing benchmarks for the government-subsidized low income Medicare Part D market coming in below our bids in a number of regions.

UnitedHealthcare's revenue growth for the three months ended March 31, 2012 was primarily due to growth in the number of individuals served and commercial premium rate increases reflecting expected underlying medical cost trends.

UnitedHealthcare's earnings from operations for the three months ended March 31, 2012 increased compared to the prior year primarily due to the factors that increased revenues and an improvement in the medical care ratio due to an increase in net favorable medical cost development and a benefit of \$130 million from updating estimates and regulatory clarifications regarding the calculations of 2011 premium rebates payable.

In March 2012, UnitedHealthcare was awarded the TRICARE West Region Managed Care Support Contract. The contract includes a transition period and five one-year option periods for health care operations. The first year of operations is anticipated to begin April 1, 2013. The administrative services contract is worth \$1.4 billion, over the five years. In 2012, we expect to incur startup costs, which will not have a material effect on our financial statements.

**Optum.** Total revenue for Optum businesses increased for the three months ended March 31, 2012 due to business growth and 2011 acquisitions at OptumHealth.

Optum's earnings from operations and operating margin for the three months ended March 31, 2012 decreased compared to 2011 due to investments across the Optum business infrastructure (primarily scaling pharmacy management services) and the reduction in Medicare Part D pharmacy membership and related prescription volumes.

The results by segment were as follows:

#### **OptumHealth**

The increase in revenues at OptumHealth for the three months ended March 31, 2012 was primarily due to 2011 acquisitions in clinical care and services for payers and the military and strong organic growth in care services and carve-out specialty risk offerings.

Earnings from operations and operating margin for the three months ended March 31, 2012 decreased compared to 2011, driven by business mix and operational investments.

## ***OptumInsight***

Revenues at OptumInsight for the three months ended March 31, 2012 were flat, as the impact of organic growth was fully offset by the divestiture of the clinical trials services business in June 2011.

The increases in earnings from operations and operating margins for the three months ended March 31, 2012 reflect an improved mix of services.

## ***OptumRx***

The increase in OptumRx revenues for the three months ended March 31, 2012 was driven by a net growth in customers served despite the reduction in UnitedHealthcare Medicare Part D plan participants. Intersegment revenues eliminated in consolidation were \$4.0 billion for both the three months ended March 31, 2012 and 2011.

OptumRx earnings from operations and operating margins for 2012 decreased as investments to support growth initiatives, including the in-sourcing of our commercial pharmacy benefit programs, and decreased prescription volume in the Medicare Part D business, more than offset the earnings contribution from greater use of generic medications.

## ***LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES***

### ***Liquidity***

#### ***Introduction***

We manage our liquidity and financial position in the context of our overall business strategy. We continually forecast and manage our cash, investments, working capital balances and capital structure to meet the short- and long-term obligations of our businesses while seeking to maintain liquidity and financial flexibility. Cash flows generated from operating activities are principally from earnings before non-cash expenses.

Our regulated subsidiaries generate significant cash flows from operations and are subject to financial regulations and standards in their respective states of domicile. Most of these regulations and standards conform to those established by the National Association of Insurance Commissioners. These standards, among other things, require these subsidiaries to maintain specified levels of statutory capital, as defined by each state, and restrict the timing and amount of dividends and other distributions that may be paid to their parent companies. Except in the case of extraordinary dividends, these standards generally permit dividends to be paid from statutory unassigned surplus of the regulated subsidiary and are limited based on the regulated subsidiary's level of statutory net income and statutory capital and surplus. These dividends are referred to as "ordinary dividends" and generally can be paid without prior regulatory approval. If the dividend, together with other dividends paid within the preceding twelve months, exceeds a specified statutory limit or is paid from sources other than earned surplus, the entire dividend is generally considered an "extraordinary dividend" and must receive prior regulatory approval.

In 2012, based on the 2011 statutory net income and statutory capital and surplus levels, the maximum amount of ordinary dividends which can be paid by our regulated subsidiaries to their parent companies is \$4.6 billion. For the three months ended March 31, 2012, our regulated subsidiaries paid their parent companies dividends of \$1.4 billion, including \$238 million of extraordinary dividends. For the year ended December 31, 2011, our regulated subsidiaries paid their parent companies dividends of \$4.5 billion, including \$1.1 billion of extraordinary dividends.

Our non-regulated businesses also generate cash flows from operations for general corporate use. Cash flows generated by these entities, combined with dividends from our regulated entities and financing through the issuance of long term debt as well as issuance of commercial paper or drawings under our committed credit facility, further strengthen our operating and financial flexibility. We use these cash flows to expand our businesses through acquisitions, reinvest in our businesses through capital expenditures, repay debt, and return capital to our shareholders through shareholder dividends and/or repurchases of our common stock, depending on market conditions.



## Summary of our Major Sources and Uses of Cash

(in millions)	Three Months Ended March 31,	
	2012	2011
Sources of cash:		
Cash provided by operating activities .....	\$ 3,586	\$ 1,224
Issuance of long-term debt and commercial paper, net of repayments .....	1,239	551
Proceeds from customer funds administered.....	1,137	1,050
Other .....	257	117
Total sources of cash.....	<u>6,219</u>	<u>2,942</u>
Uses of cash:		
Cash paid for acquisitions, net of cash assumed .....	(1,935)	(541)
Common stock repurchases .....	(991)	(620)
Purchases of property, equipment and capitalized software, net of dispositions .....	(269)	(213)
Purchases of investments, net of sales and maturities .....	(194)	(583)
Dividends paid.....	(168)	(135)
Other .....	(430)	(183)
Total uses of cash.....	<u>(3,987)</u>	<u>(2,275)</u>
Net increase in cash .....	<u>\$ 2,232</u>	<u>\$ 667</u>

### 2012 Cash Flows Compared to 2011 Cash Flows

Cash flows from operating activities increased \$2.4 billion, from 2011. The increased cash flows were primarily driven by an increase in unearned premiums due to the early receipt of the April CMS payment of approximately \$2.5 billion. See Note 4 of Notes to the Condensed Consolidated Financial Statements for further detail on the April CMS payment. We anticipate lower year over year cash flows from operations in 2012, which will include payments in the third quarter for 2011 premium rebate obligations.

Cash flows used for investing activities increased \$1.1 billion, or 79%, primarily due to increased investments in acquisitions in 2012 partially offset by a decrease in net purchases of investments.

Cash flows from financing activities increased \$264 million, or 34%, primarily due to increased net borrowings and an increase in proceeds from customer funds administered due to the early receipt of the April CMS Subsidies and drug discount payments, partially offset by an increase in share repurchases.

### Financial Condition

As of March 31, 2012, our cash, cash equivalent and available-for-sale investment balances of \$30.4 billion included \$11.7 billion of cash and cash equivalents (of which \$1.1 billion was held by non-regulated entities), \$18.1 billion of debt securities and \$577 million of investments in equity securities and venture capital funds. Given the significant portion of our portfolio held in cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. The use of different market assumptions or valuation methodologies, especially those used in valuing our \$211 million of available-for-sale Level 3 securities (those securities priced using significant unobservable inputs), may have an effect on the estimated fair value amounts of our investments. Due to the subjective nature of these assumptions, the estimates may not be indicative of the actual exit price if we had sold the investment at the measurement date. Other sources of liquidity, primarily from operating cash flows and our commercial paper program, which is supported by our \$3.0 billion bank credit facility, reduce the need to sell investments during adverse market conditions. See Note 3 of Notes to the Condensed Consolidated Financial Statements for further detail of our fair value measurements.

Our cash equivalent and investment portfolio has a weighted-average duration of 2.0 years and a weighted-average credit rating of "AA" as of March 31, 2012. Included in the debt securities balance are \$2.2 billion of state and municipal obligations that are guaranteed by a number of third parties. Due to the high underlying credit ratings of the issuers, the weighted-average credit rating of these securities with and without the guarantee was "AA" as of March 31, 2012. We do not have any significant exposure to any single guarantor (neither indirect through the guarantees, nor direct through investment in the guarantor). When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

## Capital Resources and Uses of Liquidity

In addition to cash flow from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:

**Commercial Paper.** We maintain a commercial paper borrowing program, which facilitates the private placement of unsecured debt through third-party broker-dealers. The commercial paper program is supported by the bank credit facility described below. As of March 31, 2012, we had \$245 million of commercial paper outstanding with a weighted-average annual interest rate of 0.5%.

**Bank Credit Facility.** We have a \$3.0 billion five-year revolving bank credit facility with 21 banks, which will mature in December 2016. This facility supports our commercial paper program and is available for general corporate purposes. There were no amounts outstanding under this facility as of March 31, 2012. The interest rate on borrowings is variable based on term and amount and is calculated based on the LIBOR plus a credit spread based on our senior unsecured credit ratings. As of March 31, 2012, the annual interest rate on this facility, had it been drawn, would have ranged from 1.1% to 1.6%.

Our bank credit facility contains various covenants, including requiring us to maintain a debt to debt-plus-equity ratio below 50%. Our debt to debt-plus-equity ratio, calculated as the sum of debt divided by the sum of debt and shareholders' equity, was 30.8% and 29.1% as of March 31, 2012 and December 31, 2011, respectively. We were in compliance with our debt covenants as of March 31, 2012.

**Long-term debt.** Periodically, we access capital markets and issue long-term debt for general corporate purposes and the funds may be used, for example, to meet our working capital requirements, to refinance debt, to finance acquisitions, for share repurchases or for other general corporate purposes.

In March 2012, we issued \$1 billion in senior unsecured notes. The issuance included \$600 million of 2.875% fixed-rate notes due March 2022 and \$400 million of 4.375% fixed-rate notes due March 2042.

**Credit Ratings.** Our credit ratings at March 31, 2012 were as follows:

	Moody's		Standard & Poor's		Fitch		A.M. Best	
	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook	Ratings	Outlook
Senior unsecured debt.....	A3	Stable	A-	Positive	A-	Stable	bbb+	Stable
Commercial paper.....	P-2	n/a	A-2	n/a	F1	n/a	AMB-2	n/a

The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. For example, a significant downgrade in our credit ratings or conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital. We have adopted strategies and actions toward maintaining financial flexibility to mitigate the impact of such factors on our ability to raise capital.

**Share Repurchases.** Under our Board of Directors' authorization, we maintain a common share repurchase program. Repurchases may be made from time to time in open market purchases or other types of transactions (including prepaid or structured repurchase programs), subject to certain preset parameters established by our Board. During the three months ended March 31, 2012, we repurchased 19 million shares at an average price of \$53.50 per share and an aggregate cost of \$991 million. As of March 31, 2012, we had Board authorization to purchase up to an additional 46 million shares of our common stock.

**Dividends.** In February 2012, our Board of Directors approved a quarterly dividend of \$0.1625 per share. Declaration and payment of future quarterly dividends is at the discretion of our Board and may be adjusted as business needs or market conditions change. Our annual dividend rate is \$0.65 per share, paid quarterly.

## CONTRACTUAL OBLIGATIONS AND COMMITMENTS

A summary of future obligations under our various contractual obligations and commitments as of December 31, 2011 was disclosed in our 2011 10-K. During the three months ended March 31, 2012 there were no material changes to this previously-filed information outside the ordinary course of business. However, we continually evaluate opportunities to expand our operations, including internal development of new products, programs and technology applications and acquisitions.

## **RECENTLY ISSUED ACCOUNTING STANDARDS**

We have determined that there have been no recently issued accounting standards that will have a material impact on our Consolidated Financial Statements.

## **CRITICAL ACCOUNTING ESTIMATES**

We prepared our Condensed Consolidated Financial Statements in conformity with U.S. GAAP. In preparing these Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and trends and factor in known and projected trends. On an on-going basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates and this difference would be reported in our current operations.

Our critical accounting estimates include medical costs, revenues, goodwill and intangible assets, investments, income taxes and contingent liabilities. For a detailed description of our critical accounting estimates, see “Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations” in Part II of our 2011 10-K. As of March 31, 2012, our critical accounting policies have not changed from those described in our 2011 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements in our 2011 10-K.

## **CONCENTRATIONS OF CREDIT RISK**

Investments in financial instruments such as marketable securities and accounts receivable may subject us to concentrations of credit risk. Our investments in marketable securities are managed under an investment policy authorized by our Board of Directors. This policy limits the amounts that may be invested in any one issuer and generally limits our investments to U.S. government and agency securities, state and municipal securities and corporate debt obligations that are investment grade. Concentrations of credit risk with respect to accounts receivable are limited due to the large number of employer groups and other customers that constitute our client base. As of March 31, 2012, we had an aggregate \$1.9 billion reinsurance receivable resulting from the sale of our Golden Rule Financial Corporation life and annuity business in 2005. We regularly evaluate the financial condition of the reinsurer and only record the reinsurance receivable to the extent that the amounts are deemed probable of recovery. Currently, the reinsurer is rated by A.M. Best as “A+.” As of March 31, 2012, there were no other significant concentrations of credit risk.

## **FORWARD-LOOKING STATEMENTS**

The statements, estimates, projections, guidance or outlook contained in this report include “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These statements are intended to take advantage of the “safe harbor” provisions of the PSLRA. Generally the words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “plan,” “project,” “should” and similar expressions identify forward-looking statements, which generally are not historical in nature. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. We caution that actual results could differ materially from those that management expects, depending on the outcome of certain factors.

Some factors that could cause results to differ materially from the forward-looking statements include: our ability to effectively estimate, price for and manage our medical costs, including the impact of any new coverage requirements; the potential impact that new laws or regulations, or changes in existing laws or regulations, or their enforcement or application could have on our results of operations, financial position and cash flows, including as a result of increases in medical, administrative, technology or other costs or decreases in enrollment resulting from federal, state, local and international regulations affecting the health care industry; the impact of any potential assessments for insolvent payers under state guaranty fund laws, including any that could arise out of the potential liquidation of Penn Treaty Network America Insurance Company; the ultimate impact of the Patient Protection and Affordable Care Act, which could materially and adversely affect our results of operations, financial position and cash flows through reduced revenues, increased costs, new taxes and expanded liability, or require changes to the ways in which we conduct business or put us at risk for loss of business; potential reductions in revenue received from Medicare and Medicaid programs; uncertainties regarding changes in Medicare, including potential changes in risk adjustment data validation audit and payment adjustment methodology; failure to comply with restrictions on patient privacy and data security regulations; regulatory and other risks and uncertainties associated with the pharmacy benefits management industry and our ability to successfully repatriate our pharmacy benefits management business; competitive pressures, which could affect our ability to maintain or increase our market share; the impact of challenges to our public sector contract awards; our ability to execute contracts on competitive terms with physicians, hospitals and other service professionals; our ability to attract, retain and provide support to a network of independent producers (i.e., brokers and agents) and consultants; events that

may adversely affect our relationship with AARP; increases in costs and other liabilities associated with increased litigation, government investigations, audits or reviews; the potential impact of adverse economic conditions on our revenues (including decreases in enrollment resulting from increases in the unemployment rate and commercial attrition) and results of operations; the performance of our investment portfolio; possible impairment of the value of our goodwill and intangible assets in connection with dispositions or if estimated future results do not adequately support goodwill and intangible assets recorded for our existing businesses or the businesses that we acquire; increases in health care costs resulting from large-scale medical emergencies; failure to maintain effective and efficient information systems or if our technology products otherwise do not operate as intended; misappropriation of our proprietary technology; our ability to obtain sufficient funds from our regulated subsidiaries to fund our obligations, to maintain our quarterly dividend payment cycle or to continue repurchasing shares of our common stock; failure to complete or receive anticipated benefits of acquisitions and other strategic transactions; potential downgrades in our credit ratings; and failure to achieve targeted operating cost productivity improvements, including savings resulting from technology enhancement and administrative modernization.

This list of important factors is not intended to be exhaustive. We discuss certain of these matters more fully, as well as certain risk factors that may affect our business operations, financial condition and results of operations, in our other periodic and current filings with the SEC, including our 2011 10-K. Any or all forward-looking statements we make may turn out to be wrong. They can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual future results may vary materially from expectations expressed in this report or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements.

### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Our primary market risks are exposures to (a) changes in interest rates that impact our investment income and interest expense and the fair value of certain of our fixed-rate investments and debt and (b) changes in equity prices that impact the value of our equity investments.

As of March 31, 2012, \$11.7 billion of our investments were classified as cash and cash equivalents on which interest rates received vary with market interest rates, which may materially impact our investment income. Also, \$2.3 billion of our debt and deposit liabilities as of March 31, 2012 were at interest rates that vary with market rates, either directly or through the use of related interest rate swap contracts.

The fair value of certain of our fixed-rate investments and debt also varies with market interest rates. As of March 31, 2012, \$18.6 billion of our investments were fixed-rate debt securities and \$12.1 billion of our debt was non-swapped fixed-rate term debt. An increase in market interest rates decreases the market value of fixed-rate investments and fixed-rate debt. Conversely, a decrease in market interest rates increases the market value of fixed-rate investments and fixed-rate debt.

We manage exposure to market interest rates by diversifying investments across different fixed income market sectors and debt across maturities, as well as endeavoring to match our floating-rate assets and liabilities over time, either directly or periodically through the use of interest rate swap contracts.

The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% or 2% as of March 31, 2012 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):

Increase (Decrease) in Market Interest Rate	March 31, 2012			
	Investment Income Per Annum (a)	Interest Expense Per Annum (a)	Fair Value of Investments (b)	Fair Value of Debt
2 % .....	\$ 251	\$ 46	\$ (1,255)	\$ (1,892)
1 .....	125	23	(634)	(1,004)
(1) .....	(24)	(6)	567	1,228
(2) .....	nm	nm	887	2,490

nm = not meaningful

- (a) Given the low absolute level of short-term market rates on our floating-rate assets and liabilities as of March 31, 2012 and 2011, the assumed hypothetical change in interest rates does not reflect the full 100 basis point reduction in interest income or interest expense as the rate cannot fall below zero and thus the 200 basis point reduction is not meaningful.
- (b) As of March 31, 2012, some of our investments had interest rates below 2% so the assumed hypothetical change in the fair value of investments does not reflect the full 200 basis point reduction.

As of March 31, 2012, we had \$577 million of investments in equity securities and venture capital funds, a portion of which were invested in various public and non-public companies concentrated in the areas of health care delivery and related information technologies. Market conditions that affect the value of health care or technology stocks will impact the value of our equity investments.

#### ITEM 4. CONTROLS AND PROCEDURES

##### *EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES*

We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.

In connection with the filing of this Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2012. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of March 31, 2012.

##### *CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING*

There have been no changes in our internal control over financial reporting during the quarter ended March 31, 2012 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

### PART II. OTHER INFORMATION

#### ITEM 1. LEGAL PROCEEDINGS

A description of our legal proceedings is included in and incorporated by reference to Note 8 of the Notes to the Condensed Consolidated Financial Statements contained in Part I, Item 1 of this report.

#### ITEM 1A. RISK FACTORS

In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, "Risk Factors" of our 2011 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2011 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

There have been no material changes to the risk factors disclosed in our 2011 10-K.

#### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

##### Issuer Purchases of Equity Securities (a) First Quarter 2012

For the Month Ended	Total Number of Shares Purchased	Average Price Paid per Share	Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs	Maximum Number of Shares That May Yet Be Purchased Under The Plans or Programs
	(in millions)		(in millions)	(in millions)
January 31, 2012 .....	7	\$ 51.98	7	58
February 29, 2012 .....	7	53.74	7	51
March 31, 2012 .....	5	55.18	5	46
Total.....	19	\$ 53.50	19	

- (a) In November 1997, our Board of Directors adopted a share repurchase program, which the Board evaluates periodically. In May 2011, the Board renewed our share repurchase program with an authorization to repurchase up to 110 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs). There is no established expiration date for the program.

**ITEM 5. OTHER INFORMATION**

In the first quarter of 2012, the Company adopted ASU 2011-05, “Comprehensive Income (Topic 220) - Presentation of Comprehensive Income” (ASU 2011-05). ASU 2011-05 requires entities to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements and eliminates the option to present the components of other comprehensive income as a part of the statement of equity.

The table below reflects the retrospective application of this guidance for each of the three years covered by our 2011 10-K Total Comprehensive income for Schedule I “Condensed Financial Information of Registrant (Parent Company Only)” would equal comprehensive income as presented below.

(in millions)	For the Year Ended December 31,		
	2011	2010	2009
Net earnings.....	\$ 5,142	\$ 4,634	\$ 3,822
Other comprehensive income (loss):			
Gross unrealized holding gains on investment securities during the period.....	422	74	501
Income tax expense.....	(154)	(26)	(187)
Total unrealized gains, net of tax.....	268	48	314
Gross reclassification adjustment for net realized gains included in net earnings.....	(113)	(71)	(11)
Income tax benefit.....	41	26	4
Total reclassification adjustment, net of tax.....	(72)	(45)	(7)
Foreign currency translation adjustments.....	13	(4)	(2)
Other comprehensive income (loss).....	209	(1)	305
Comprehensive income.....	\$ 5,351	\$ 4,633	\$ 4,127

## ITEM 6. EXHIBITS \*\*

The following exhibits are filed in response to Item 601 of Regulation S-K.

- 3.1 Third Restated Articles of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated May 29, 2007)
- 3.2 Fourth Amended and Restated Bylaws of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated October 23, 2009)
- 4.1 Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
- 4.2 Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between the UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
- 4.3 Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
- 4.4 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
- \*10.1 Amended and Restated Employment Agreement, dated as of March 26, 2012, between United HealthCare Services, Inc. and Larry C. Renfro
- 12.1 Ratio of Earnings to Fixed Charges
- 31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101 The following materials from UnitedHealth Group Incorporated's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 filed on May 3, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Shareholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.

---

\* Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.

\*\* Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

UNITEDHEALTH GROUP INCORPORATED

<u>/s/ STEPHEN J. HEMSLEY</u> <b>Stephen J. Hemsley</b>	President and Chief Executive Officer (principal executive officer)	Dated: May 3, 2012
<u>/s/ DAVID S. WICHMANN</u> <b>David S. Wichmann</b>	Executive Vice President and Chief Financial Officer of UnitedHealth Group and President of UnitedHealth Group Operations (principal financial officer)	Dated: May 3, 2012
<u>/s/ ERIC S. RANGEN</u> <b>Eric S. Rangen</b>	Senior Vice President and Chief Accounting Officer (principal accounting officer)	Dated: May 3, 2012



## EXHIBIT INDEX\*\*

- 3.1 Third Restated Articles of Incorporation of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated May 29, 2007)
- 3.2 Fourth Amended and Restated Bylaws of UnitedHealth Group Incorporated (incorporated by reference to Exhibit 3.1 to the Company's Current Report on Form 8-K dated October 23, 2009)
- 4.1 Senior Indenture, dated as of November 15, 1998, between United HealthCare Corporation and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3/A, SEC File Number 333-66013, filed on January 11, 1999)
- 4.2 Amendment, dated as of November 6, 2000, to Senior Indenture, dated as of November 15, 1998, between the UnitedHealth Group Incorporated and The Bank of New York (incorporated by reference to Exhibit 4.1 to the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2001)
- 4.3 Instrument of Resignation, Appointment and Acceptance of Trustee, dated January 8, 2007, pursuant to the Senior Indenture, dated November 15, 1998, amended November 6, 2000, among UnitedHealth Group Incorporated, The Bank of New York and Wilmington Trust Company (incorporated by reference to Exhibit 4.3 to the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007)
- 4.4 Indenture, dated as of February 4, 2008, between UnitedHealth Group Incorporated and U.S. Bank National Association (incorporated by reference to Exhibit 4.1 to the Company's Registration Statement on Form S-3, SEC File Number 333-149031, filed on February 4, 2008)
- \*10.1 Amended and Restated Employment Agreement, dated as of March 26, 2012, between United HealthCare Services, Inc. and Larry C. Renfro
- 12.1 Ratio of Earnings to Fixed Charges
- 31.1 Certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.1 Certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
- 101 The following materials from UnitedHealth Group Incorporated's Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 filed on May 3, 2012, formatted in XBRL (eXtensible Business Reporting Language): (i) Condensed Consolidated Balance Sheets, (ii) Condensed Consolidated Statements of Operations, (iii) Condensed Consolidated Statements of Comprehensive Income, (iv) Condensed Consolidated Statements of Changes in Shareholders' Equity, (v) Condensed Consolidated Statements of Cash Flows, and (vi) Notes to the Condensed Consolidated Financial Statements.

---

\* Denotes management contracts and compensation plans in which certain directors and named executive officers participate and which are being filed pursuant to Item 601(b)(10)(iii)(A) of Regulation S-K.

\*\* Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.